CLAIMS

1. Use of a dosage form comprising an effective amount of troriluzole in the manufacture of a medicament for the treatment of obsessive-compulsive disorder in a patient in need thereof, wherein the patient has a median Y-BOCS score of 26 or greater.

2. The use of Claim 1, wherein the dosage form is to be administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least -3.4 points from baseline.

3. The use of Claim 1, wherein the dosage form is to be administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.5 points compared to placebo.

4. The use of Claim 1, wherein the dosage form is to be administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least -5.1 points from baseline.

5. The use of Claim 1, wherein the dosage form is to be administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 1.5 points compared to placebo.

6. The use of Claim 1, wherein the dosage form is to be administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of -5.9 points from baseline.

7. The use of Claim 1, wherein the dosage form is to be administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 1.0 points compared to placebo.

8. The use of Claim 1, wherein the dosage form is to be administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least -4.1 points from baseline.

9. The use of Claim 1, wherein the dosage form is to be administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.6 points compared to placebo.

10. The use of Claim 1, wherein the dosage form is to be administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least -6.0 points from baseline.

11. The use of Claim 1, wherein the dosage form is to be administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 2.9 points compared to placebo.

12. The use of Claim 1, wherein the dosage form is to be administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of -7.0 points from baseline.

13. The use of Claim 1, wherein the dosage form is to be administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 2.4 points compared to placebo.

14. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 200 mg or greater.

15. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 250 mg or greater.

16. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 300 mg or greater.

17. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 350 mg or greater.

18. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 400 mg or greater.

19. The use of Claim 1, wherein the dosage form comprises troriluzole in an amount of 450 mg or greater.

20. The dosage form of Claim 1, comprising troriluzole in an amount of 500 mg or greater.